Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)
A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults
Sponsor: Kirby Institute
Listed as NCT01159223, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Kirby Institute, it has been updated 7 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kirby Institute
- National Health Security Office, Thailand
- The HIV Netherlands Australia Thailand Research Collaboration
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bangkok, Thailand
- • Chiang Rai, Thailand
- • Chon Buri, Thailand
- • Khon Kaen, Thailand
- • Nonthaburi, Thailand
- • Sanpathong, Thailand